Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice

Journal of Lipid Research

Volumn 56, Issue 4, 2015, Pages 801-809

  Shende, Vikram Ravindra ^a,b   Wu, Minhao ^a   Singh, Amar Bahadur ^a,b   Dong, Bin ^a   Kan, Chin Fung Kelvin ^a   Liu, Jingwen ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatic nuclear factor 1 ; Hepatic nuclear factor 1 ; Low density lipoprotein cholesterol; Low density lipoprotein receptor; Proprotein convertase subtilisin kexin type 9

Indexed keywords

ADENOVIRUS VECTOR; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 1BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; HNF1B PROTEIN, MOUSE; PCSK9 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CELL LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE EXPRESSION; GENE SILENCING; HEPG2 CELL LINE; MALE; MOUSE; NONHUMAN; PCSK9 GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE SPECIFICITY; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; ANTIBODY SPECIFICITY; BLOOD; CYTOLOGY; DEFICIENCY; DIET; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HUMAN; LIVER; METABOLISM;

ANIMALS; CHOLESTEROL, LDL; DIET; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HEP G2 CELLS; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HUMANS; LIVER; MALE; MICE; ORGAN SPECIFICITY; PROPROTEIN CONVERTASES; RNA, MESSENGER; SERINE ENDOPEPTIDASES;

EID: 84927560589     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M052969     Document Type: Article

References (37)

1. Grundy, S. M., J. I. Cleeman, C. N. Merz, H. B. Brewer, Jr., L. T. Clark, D. B. Hunninghake, R. C. Pasternak, S. C. Smith, Jr., and N. J. Stone. 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J. Am. Coll. Cardiol. 44: 720-732.
2. Spady, D. K. 1992. Hepatic clearance of plasma low density lipoproteins. Semin. Liver Dis. 12: 373-385.
3. Brown, M. S., and J. L. Goldstein. 1986. A receptor-mediated pathway for cholesterol homeostasis. Science. 232: 34-47.
4. Maxwell, K. N., and J. L. Breslow. 2004. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. USA. 101: 7100-7105.
5. Qian, Y-W., R. J. Schmidt, Y. Zhang, S. Chu, A. Lin, H. Wang, X. Wang, T. P. Beyer, W. R. Bensch, W. Li, et al. 2007. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J. Lipid Res. 48: 1488-1498.
6. Seidah, N. G., S. Benjannet, L. Wickham, J. Marcinkiewicz, J. Bélanger, S. Stifani, A. Basak, A. Prat, and M. Chrétien. 2003. The secretory proprotein convertase neutal apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. USA. 100: 928-933.
7. Benjannet, S., D. Rhainds, R. Essalmani, J. Mayne, L. Wickham, W. Jin, M. C. Asselin, J. Hamelin, M. Varret, D. Allard, et al. 2004. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279: 48865-48875.
8. Zhang, D. W., T. A. Lagace, R. Garuti, Z. Zhao, M. McDonald, J. D. Horton, J. C. Cohen, and H. Hobbs. 2007. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 282: 18602-18612.
9. Fisher, T. S., S. P. Lo, S. Pandit, M. Mattu, J. C. Santoro, D. Wisniewski, R. T. Cummings, A. Calzetta, R. M. Cubbon, P. A. Fischer, et al. 2007. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J. Biol. Chem. 282: 20502-20512.
10. Abifadel, M., M. Varret, J. P. Rabes, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, D. Erlich, et al. 2003. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34: 154-156.
11. Benjannet, S., J. Hamelin, M. Chretien, and N. G. Seidah. 2012. Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation. J. Biol. Chem. 287: 33745-33755.
12. Jeong, H. J., H-S. Lee, K-S. Kim, Y-K. Kim, D. Yoon, and S. W. Park. 2008. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J. Lipid Res. 49: 399-409.
13. Horton, J. D., N. A. Shah, J. A. Warrington, N. N. Anderson, S. W. Park, S. W. Park, M. S. Brown, and J. L. Goldstein. 2003. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. USA. 100: 12027-12032.
14. Maxwell, K.N., Soccio, R.E., Duncan, E.M., Sehayek, E., and Breslow, J.L. 2003. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J. Lipid Res. 44: 2109-2119.
15. Dubuc, G., A. Chamberland, H. Wassef, J. Davignon, N. G. Seidah, L. Bernier, and A. Prat. 2004. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 24: 1454-1459.
16. Rashid, S., D. E. Curtis, R. Garuti, N. N. Anderson, Y. Bashmakov, Y. K. Ho, R. E. Hammer, Y-A. Moon, and J. D. Horton. 2005. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. USA. 102: 5374-5379.
17. Attie, A. D., and N. G. Seidah. 2005. Dual regulation of the LDL receptor-some clarity and new questions. Cell Metab. 1: 290-292.
18. Li, H., B. Dong, S. W. Park, H-S. Lee, W. Chen, and J. Liu. 2009. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J. Biol. Chem. 284: 28885-28895.
19. Cereghini, S. 1996. Liver-enriched transcription factors and hepatocyte differentiation. FASEB J. 10: 267-282.
20. Mendel, D. B., L. P. Hansen, M. K. Graves, P. B. Conley, and G. R. Crabtree. 1991. HNF-1α and HNF-1 β (vHNF-1) share dimerization and homeo domains, but not activation domains, and form heterodimers in vitro. Genes Dev. 5: 1042-1056.
21. Mendel, D. B., and G. R. Crabtree. 1991. HNF-1, a member of a novel class of dimerizing homeodomain proteins. J. Biol. Chem. 266: 677-680.
22. Pontoglio, M., J. Barra, M. Hadchouel, A. Doyen, C. Kress, J. P. Bach, C. Babinet, and M. Yaniv. 1996. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell. 84: 575-585.
23. Pontoglio, M., S. Sreenan, M. Roe, W. Pugh, D. Ostrega, A. Doyen, A. J. Pick, A. Baldwin, G. Velho, P. Froguel, et al. 1998. Defective insulin secretion in hepatocyte nuclear factor 1alpha-deficient mice. J. Clin. Invest. 101: 2215-2222.
24. Coffinier, C., D. Thepot, C. Babinet, M. Yaniv, and J. Barra. 1999. Essential role for the homeoprotein vHNF1/HNF1beta in visceral endoderm differentiation. Development. 126: 4785-4794.
25. Barbacci, E., M. Reber, M. O. Ott, C. Breillat, F. Huetz, and S. Cereghini. 1999. Variant hepatocyte nuclear factor 1 is required for visceral endoderm specification. Development. 126: 4795-4805.
26. Mitchell, S. M., and T. M. Frayling. 2002. The role of transcription factors in maturity-onset diabetes of the young. Mol. Genet. Metab. 77: 35-43.
27. Ryffel, G. U. 2001. Mutations in the human genes encoding the transcription factors of the hepatocyte nuclear factor (HNF)1 and HNF4 families: functional and pathological consequences. J. Mol. Endocrinol. 27: 11-29.
28. Pelletier, L., S. Rebouissou, A. Paris, E. Rathahao-Paris, E. Perdu, P. Bioulac-Sage, S. Imbeaud, and J. Zucman-Rossi. 2010. Loss of hepatocyte nuclear factor 1alpha function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis. Hepatology. 51: 557-566.
29. Shih, D. Q., M. Bussen, E. Sehayek, M. Ananthanarayanan, B. L. Shneider, F. J. Suchy, S. Shefer, J. S. Bollileni, F. J. Gonzalez, J. L. Breslow, et al. 2001. Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat. Genet. 27: 375-382.
30. Servitja, J-M., M. Pignatelli, M. A. Maestro, C. Cardalda, S. F. Boj, J. Lozano, E. Blanco, A. Lafuente, M. I. McCarthy, L. Sumoy, et al. 2009. HNF1α (MODY3) controls tissue-specific transcription programs and exerts opposed effects on cell growth in pancreatic islets and liver. Mol. Cell. Biol. 29: 2945-2959.
31. Ai, D., C. Chen, S. Han, A. Ganda, A. J. Murphy, R. Haeusler, E. Thorp, D. Accili, J. D. Horton, and A. R. Tall. 2012. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. J. Clin. Invest. 122: 1262-1270.
32. Shih, D. Q., S. Screenan, K. N. Munoz, L. Philipson, M. Pontoglio, M. Yaniv, K. S. Polonsky, and M. Stoffel. 2001. Loss of HNF-1alpha function in mice leads to abnormal expression of genes involved in pancreatic islet development and metabolism. Diabetes. 50: 2472-2480.
33. Ragozin, S., A. Niemeier, A. Laatsch, B. Loeffler, M. Merkel, U. Beisiegel, and J. Heeren. 2005. Knockdown of hepatic ABCA1 by RNA interference decreases plasma HDL cholesterol levels and influences postprandial lipemia in mice. Arterioscler. Thromb. Vasc. Biol. 25: 1433-1438.
34. Jin, W., X. Wang, J. S. Millar, T. Quertermous, G. H. Rothblat, J. M. Glick, and D. J. Rader. 2007. Hepatic proprotein convertases modulate HDL metabolism. Cell Metab. 6: 129-136.
35. Singh, A. B., C. F. Kan, V. Shende, B. Dong, and J. Liu. 2014. A novel posttranscriptional mechanism for dietary cholesterol-mediated suppression of liver LDL receptor expression. J. Lipid Res. 55: 1397-1407.
36. Odom, D. T., N. Zizlsperger, D. B. Gordon, G. W. Bell, N. J. Rinaldi, H. L. Murray, T. L. Volkert, J. Schreiber, P. A. Rolfe, D. K. Gifford, et al. 2004. Control of pancreas and liver gene expression by HNF transcription factors. Science. 303: 1378-1381.
37. Dong, B., M. Wu, H. Li, F. B. Kraemer, K. Adeli, N. G. Seidah, S. W. Park, and J. Liu. 2010. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J. Lipid Res. 51: 1486-1495.